Medivir Appoints Jens Lindberg as Chief Executive Officer
STOCKHOLM, Oct. 25, 2021 -- (Healthcare Sales & Marketing Network) -- Medivir AB (Nasdaq Stockholm: MVIR) today announces that the Board of Directors has appointed Jens Lindberg as CEO of the company. Jens Lindberg has extensive experience from the pharma... Biopharmaceuticals, Personnel Medivir, hepatocellular carcinoma, liver cancer (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - October 25, 2021 Category: Pharmaceuticals Source Type: news

Sirtex Medical and China Grand Pharmaceutical announce successful first administration of SIR-Spheres(R) Y-90 resin microspheres in China
WOBURN, Mass., Oct. 11, 2021 -- (Healthcare Sales & Marketing Network) -- Sirtex Medical ("Sirtex"), a leading manufacturer of targeted liver cancer therapies, announced today that the first procedure of selective internal radiation therapy (SIR... Devices, Oncology Sirtex Medical, SIR-Spheres, Y-90 resin microspheres, hepatocellular carcinoma (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - October 11, 2021 Category: Pharmaceuticals Source Type: news

Hepatocellular carcinoma screening in cirrhotic patients is worth it in Australia
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - October 1, 2021 Category: Drugs & Pharmacology Source Type: news

Use Live Donors for Liver Transplants for HCC Patients Use Live Donors for Liver Transplants for HCC Patients
For patients with hepatocelluar carcinoma (HCC), liver transplant from a live donor improves survival and frees up organs from deceased donors for other patients on the long waiting list.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 24, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Wake Forest School of Medicine Research shows radio-wave therapy is safe for liver cancer patients and improves overall survival
Researchers at Wake Forest School of Medicine have shown that a targeted therapy using non-thermal radio waves is safe to use in the treatment of hepatocellular carcinoma (HCC), the most common type of liver cancer. The therapy also showed a benefit in overall survival. The study findings appear online in 4Open, a journal published by EDP Sciences. “HCC accounts for nearly 90% of all liver cancers, and current survival rates are between six and 20 months,” said Dr. Boris Pasche, chair of cancer… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - September 15, 2021 Category: Biotechnology Authors: Atrium Health Wake Forest Baptist Source Type: news

Wake Forest School of Medicine Research shows radio-wave therapy is safe for liver cancer patients and improves overall survival
Researchers at Wake Forest School of Medicine have shown that a targeted therapy using non-thermal radio waves is safe to use in the treatment of hepatocellular carcinoma (HCC), the most common type of liver cancer. The therapy also showed a benefit in overall survival. The study findings appear online in 4Open, a journal published by EDP Sciences. “HCC accounts for nearly 90% of all liver cancers, and current survival rates are between six and 20 months,” said Dr. Boris Pasche, chair of cancer… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - September 15, 2021 Category: American Health Authors: Atrium Health Wake Forest Baptist Source Type: news

Ramucirumab Shows Survival Benefits with Pleural Mesothelioma
Adding the drug ramucirumab to gemcitabine chemotherapy worked especially well in a recent clinical trial involving second-line treatment for patients with pleural mesothelioma. Ramucirumab, an immunotherapy drug also known by the brand name Cyramza, is a monoclonal antibody that works by targeting and restricting a protein that stimulates blood vessel growth within tumors. Impressive results in the phase II clinical trial moved the drug combination closer to filling the long-standing void for a second-line mesothelioma treatment. The Lancet Oncology recently published results of the study, which was conducted in ...
Source: Asbestos and Mesothelioma News - September 13, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

PET identifies early responders to liver cancer treatment
PET imaging can predict how liver cancer patients are going to respond earl...Read more on AuntMinnie.comRelated Reading: AI can identify hepatocellular carcinoma on liver CT exams FCH-PET shines in guiding parathyroid surgery Study evaluates safety of new liver cancer treatment Sirtex launches study to assess SIR-Spheres for HCC US microbubble destruction may improve TARE response (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - September 10, 2021 Category: Radiology Source Type: news

Fraction of Cirrhosis and HCC Attributable to Hepatitis B and C Fraction of Cirrhosis and HCC Attributable to Hepatitis B and C
This study assessed a protocol developed by WHO to collect data on the worldwide fraction of cirrhosis and hepatocellular carcinoma attributable to hepatitis B and C. How might it be improved?Journal of Viral Hepatitis (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - September 6, 2021 Category: Surgery Tags: Gastroenterology Journal Article Source Type: news

Nonselective Beta-blockers and HCC Risk Among Cirrhotic Patients Nonselective Beta-blockers and HCC Risk Among Cirrhotic Patients
Might nonselective beta-blockers such as carvedilol, nadolol, and propranolol decrease the risk of hepatocellular carcinoma among patients with cirrhosis?Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 6, 2021 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Effect of NSAIDs and APT on Incidence and Recurrence of HCC Effect of NSAIDs and APT on Incidence and Recurrence of HCC
This study investigated whether NSAIDs or aspirin might have an impact on hepatocellular carcinoma incidence or recurrence among high-risk persons with chronic liver disease.Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 1, 2021 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

High Success Rates With Down-Staging of Liver Cancer Prior to Transplant High Success Rates With Down-Staging of Liver Cancer Prior to Transplant
Down-staging of hepatocellular carcinoma prior to liver transplant based on UNOS criteria is successful most of the time using either chemoembolization or Y-90 radioembolization, new research indicates.Reuters Health Information (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - August 30, 2021 Category: Gastroenterology Tags: Hematology-Oncology News Source Type: news

PET recommended over bone scintigraphy in pediatric sarcoma
PET imaging is more effective than bone scintigraphy for detecting metastati...Read more on AuntMinnie.comRelated Reading: Body position on x-ray affects radiation dose in children Deep learning classifies brain tumors on single MRI scans AI can identify hepatocellular carcinoma on liver CT exams Black women less likely to receive breast surgery follow-up MRI offers kids radiation-free chemo response tracking (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - August 13, 2021 Category: Radiology Source Type: news

AI can identify hepatocellular carcinoma on liver CT exams
An artificial intelligence (AI) algorithm was able to identify hepatocellula...Read more on AuntMinnie.comRelated Reading: Short ultrasound screening intervals improve liver cancer outcomes Abbreviated MRI shows potential for HCC surveillance Deep learning detects HCC on contrast-enhanced MRI CE-MRI with CT extends life for patients with liver cancer ISCT: Will AI for CT be radiology's killer app? (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - August 10, 2021 Category: Radiology Source Type: news

Coffee protects against liver cancer while alcohol is linked with numerous cancers
Alcohol consumption is a major risk factor for several cancers including head & neck (mouth, pharynx, larynx), oesophageal and bowel cancer - as well as the more widely known links to breast and liver cancer - according to a new study funded by World Cancer Research Fund (WCRF)(1), and published this week in Nature Communications. The study also found increased coffee consumption was associated with a lower risk of developing liver cancer and basal cell carcinoma of the skin. (Source: World Pharma News)
Source: World Pharma News - August 4, 2021 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

US FDA grants Priority Review to Roche ’s Tecentriq as adjuvant treatment for certain people with early non-small cell lung cancer
Basel, 3 August 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has accepted the company ’s supplemental Biologics License Application (sBLA) and granted Priority Review for Tecentriq® (atezolizumab) as adjuvant treatment following surgery and platinum-based chemotherapy for people with non-small cell lung cancer (NSCLC) whose tumours express PD-L1≥1%, as determined by an FDA-appro ved test. The FDA is reviewing the application under the Real-Time Oncology Review pilot programme, which aims to explore a more efficient review process to ensure safe and ef...
Source: Roche Media News - August 3, 2021 Category: Pharmaceuticals Source Type: news

US FDA grants Priority Review to Roche ’s Tecentriq as adjuvant treatment for certain people with early non-small cell lung cancer
Basel, 3 August 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has accepted the company ’s supplemental Biologics License Application (sBLA) and granted Priority Review for Tecentriq® (atezolizumab) as adjuvant treatment following surgery and platinum-based chemotherapy for people with non-small cell lung cancer (NSCLC) whose tumours express PD-L1≥1%, as determined by an FDA-appro ved test. The FDA is reviewing the application under the Real-Time Oncology Review pilot programme, which aims to explore a more efficient review process to ensure safe and ef...
Source: Roche Investor Update - August 3, 2021 Category: Pharmaceuticals Source Type: news

Study Supports Chemopreventive Effect of Statins on Liver Cancer in NASH Cirrhosis Study Supports Chemopreventive Effect of Statins on Liver Cancer in NASH Cirrhosis
New research provides supporting evidence for chemopreventive effects of statins on hepatocellular carcinoma in patients with nonalcoholic steatohepatitis cirrhosis.Reuters Health Information (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - July 20, 2021 Category: Gastroenterology Tags: Hematology-Oncology News Source Type: news

Hepatocellular Carcinoma, Novel Therapies on the Horizon Hepatocellular Carcinoma, Novel Therapies on the Horizon
Recent advancements have led to the identification and development of potential new treatment options for hepatocellular carcinoma.Chinese Clinical Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 15, 2021 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Study sheds light on precise personalized hepatocellular carcinoma medicine
(Dalian Institute of Chemical Physics, Chinese Academy Sciences) Scientists identified hepatocellular carcinoma (HCC) subtypes with distinctive metabolic phenotypes through bioinformatics and machine learning methods, and elucidated the potential mechanisms based on a metabolite-protein interaction network and multi-omics data. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 12, 2021 Category: Cancer & Oncology Source Type: news

Tislelizumab Benefit in HCC Undimmed by Prior Therapies Tislelizumab Benefit in HCC Undimmed by Prior Therapies
Patients with advanced hepatocellular carcinoma (HCC) can achieve durable responses, and overall survival is"encouraging" with the novel immunotherapy, even after multiple prior therapies.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - July 6, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

More Frequent Ultrasound Screening for People at High Risk for Liver Cancer May Be Worth It More Frequent Ultrasound Screening for People at High Risk for Liver Cancer May Be Worth It
Regular ultrasound screening with an interval between six and 12 months or less may lead to earlier detection of hepatocellular carcinoma in high-risk patients, according to a study from Taiwan.Reuters Health Information (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - July 2, 2021 Category: Gastroenterology Tags: Hematology-Oncology News Source Type: news

Oncotarget: Treatment outcomes in patients with advanced hepatocellular carcinoma
(Impact Journals LLC) In CTP class A patients, IGF/CTP score B was associated with shorter PFS and OS (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 28, 2021 Category: Cancer & Oncology Source Type: news

Genetic study of liver cancer reveals new drug target
(PLOS) Drugs targeting the gene MAGEA3 may help block the growth of hepatocellular carcinoma (HCC), the most common type of primary liver cancer and one of the leading causes of cancer deaths in the country. That's one conclusion of a new study analyzing the genetics of HCC tumors published June 24th in the journal PLOS Genetics by Augusto Villanueva of the Icahn School of Medicine at Mount Sinai and colleagues. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 24, 2021 Category: Cancer & Oncology Source Type: news

MD Anderson research highlights for June 16, 2021
(University of Texas M. D. Anderson Cancer Center) The University of Texas MD Anderson Cancer Center's Research Highlights provides a glimpse into recently published studies in basic, translational and clinical cancer research from MD Anderson experts. Current advances include a new combination therapy for acute myeloid leukemia (AML), a greater understanding of persistent conditions after AML remission, the discovery of a universal biomarker for exosomes, the identification of a tumor suppressor gene in hepatocellular carcinoma (HCC) and characterization of a new target to treat Clostridioides difficile (C. difficile) inf...
Source: EurekAlert! - Cancer - June 16, 2021 Category: Cancer & Oncology Source Type: news

Neoadjuvant and Adjuvant Treatment Approaches for HCC Neoadjuvant and Adjuvant Treatment Approaches for HCC
Learn more about the current neoadjuvant and adjuvant treatment strategies for hepatocellular carcinoma and the promising new options on the horizon.Chinese Clinical Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 15, 2021 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Toward the first drug to treat a rare, lethal liver cancer
(Rockefeller University) After scouring more than 5,000 compounds, scientists have identified several new classes of therapeutics that may help treat fibrolamellar carcinoma. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 14, 2021 Category: Cancer & Oncology Source Type: news

Oncotarget: The drug sensitivity of hepatocellular cancer cells
(Impact Journals LLC) 'Hepatocellular carcinoma (HCC) is the third leading cause of cancer related death worldwide, with a poor median survival time after diagnosis of six months.' (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 7, 2021 Category: Cancer & Oncology Source Type: news

Oncotarget: Inflammatory microenvironment & hepatic macrophage in hepatocellular carcinoma
(Impact Journals LLC) " The incidence of hepatocellular carcinoma (HCC) is increasing worldwide, and HCC is amongst the leading causes of cancer death globally. " (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 4, 2021 Category: International Medicine & Public Health Source Type: news

Transarterial embolisation not cost effective vs sorafenib for hepatocellular carcinoma
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - June 1, 2021 Category: Drugs & Pharmacology Source Type: news

Indigenous Americans: Global DNA pattern and gene expression signature in liver cancer
(Impact Journals LLC) Hepatocellular carcinoma (HCC), the main form of primary liver cancer, is one of the leading causes of tumor-related death worldwide. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 31, 2021 Category: Cancer & Oncology Source Type: news

HCV Cure Before HCC Diagnosis Associated With Improved Survival HCV Cure Before HCC Diagnosis Associated With Improved Survival
Do patients with HCV-related hepatocellular carcinoma who have achieved HCV cure before HCC diagnosis have improved survival compared with patients who are viraemic at HCC diagnosis?Journal of Viral Hepatitis (Source: Medscape Transplantation Headlines)
Source: Medscape Transplantation Headlines - May 25, 2021 Category: Transplant Surgery Tags: Gastroenterology Journal Article Source Type: news

Bariatric Surgery Reduces the Incidence of HCC Bariatric Surgery Reduces the Incidence of HCC
This study assessed the impact of bariatric surgery on the incidence of hepatocellular carcinoma in obese patients.Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 17, 2021 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Landmark study launched to detect liver cancer early in Singapore
(SingHealth) Only 20% of primary liver cancer or hepatocellular carcinoma (HCC) are diagnosed at an early stage, which makes early detection an urgent, unmet healthcare need.The study aims to develop more accurate diagnostics for early HCC, an AI algorithm to predict an individual's risk of developing HCC, and discover novel molecular targets to prevent the development of HCC.The study aims to recruit 2,000 participants at high risk of developing HCC from six healthcare institutions and eight polyclinics across Singapore. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 3, 2021 Category: Cancer & Oncology Source Type: news

Landscape study launched to detect liver cancer early in Singapore
(Duke-NUS Medical School) - Only 20% of primary liver cancer or hepatocellular carcinoma (HCC) are diagnosed at an early stage, which makes early detection an urgent, unmet healthcare need.- Study aims to develop more accurate diagnostics for early HCC, an AI algorithm to predict an individual's risk of developing HCC, and discover novel molecular targets to prevent the development of HCC.- Study aims to recruit 2,000 participants at high risk of developing HCC from six healthcare institutions and eight polyclinics across Singapore. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 3, 2021 Category: International Medicine & Public Health Source Type: news

Landmark study launched to detect liver cancer early in Singapore
(Duke-NUS Medical School) - Only 20% of primary liver cancer or hepatocellular carcinoma (HCC) are diagnosed at an early stage, which makes early detection an urgent, unmet healthcare need.- Study aims to develop more accurate diagnostics for early HCC, an AI algorithm to predict an individual's risk of developing HCC, and discover novel molecular targets to prevent the development of HCC.- Study aims to recruit 2,000 participants at high risk of developing HCC from six healthcare institutions and eight polyclinics across Singapore. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 3, 2021 Category: Cancer & Oncology Source Type: news

Cost-effectiveness evidence of hepatocellular carcinoma screening reviewed
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - May 1, 2021 Category: Drugs & Pharmacology Source Type: news

US FDA Advisory Committee votes in favour of maintaining accelerated approval of Roche ’s Tecentriq for PD-L1-positive, metastatic triple-negative breast cancer
This study did not meet its primary endpoint of PFS for the initial (first-line) treatment of people with mTNBC in the PD-L1-positive population. As the clinically meaningful benefit demonstrated in the IMpassion130 study remains, Roche looks forward to continuing to work with the FDA to determine next steps with regard to Tecentriq in this indication.Roche remains committed to following the science to better understand cancer, including which patients may benefit most from immunotherapy treatment. Tecentriq has already demonstrated its transformational role in areas of high medical need and is a first in class medicine ap...
Source: Roche Media News - April 27, 2021 Category: Pharmaceuticals Source Type: news

US FDA Advisory Committee votes in favour of maintaining accelerated approval of Roche ’s Tecentriq for PD-L1-positive, metastatic triple-negative breast cancer
This study did not meet its primary endpoint of PFS for the initial (first-line) treatment of people with mTNBC in the PD-L1-positive population. As the clinically meaningful benefit demonstrated in the IMpassion130 study remains, Roche looks forward to continuing to work with the FDA to determine next steps with regard to Tecentriq in this indication.Roche remains committed to following the science to better understand cancer, including which patients may benefit most from immunotherapy treatment. Tecentriq has already demonstrated its transformational role in areas of high medical need and is a first in class medicine ap...
Source: Roche Investor Update - April 27, 2021 Category: Pharmaceuticals Source Type: news

Antibiotics May Prolong PFS in HCC Patients on Immunotherapy Antibiotics May Prolong PFS in HCC Patients on Immunotherapy
Taking antibiotics 30 days before or after starting an immune checkpoint inhibitor was associated with a benefit in progression-free survival (PFS) for patients with hepatocellular carcinoma.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 21, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Detecting Antibodies to p16 Protein-Derived Peptides in HCC Detecting Antibodies to p16 Protein-Derived Peptides in HCC
This study suggests that circulating IgG antibodies to p16 protein might be a useful biomarker for hepatocellular carcinoma prognosis assessment as well as early HCC diagnosis.Laboratory Medicine (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 21, 2021 Category: Consumer Health News Tags: Pathology & Lab Medicine Journal Article Source Type: news

New Combo Shows Benefit Even in Patients With High-Risk HCC New Combo Shows Benefit Even in Patients With High-Risk HCC
Updated data from the IMBRave150 trial show benefit for the combination of atezolizumab with bevacizumab even in patients with high-risk hepatocellular carcinoma.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 14, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Monofocal Hepatocellular Carcinoma: How Much Does Size Matter? Monofocal Hepatocellular Carcinoma: How Much Does Size Matter?
This study evaluated the appropriate staging of large monofocal hepatocellular carcinomas. How should tumor size impact treatment?Liver International (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 25, 2021 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Sirtex Medical announces new SIR-Spheres(R) DOORwaY-90 Study: The first prospective multicenter U.S.-based trial for registration as first-line treatment for hepatocellular carcinoma
WOBURN, Mass., March 22, 2021 -- (Healthcare Sales & Marketing Network) -- Sirtex Medical ("Sirtex"), a leading manufacturer of targeted liver cancer therapies, announced full FDA approval of the DOORwaY90 Study, a trial evaluating the safety an... Devices, Oncology Sirtex Medical, SIR-Spheres, Y-90 resin microspheres, hepatocellular carcinoma (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 22, 2021 Category: Pharmaceuticals Source Type: news

Pivotal Phase III study shows Roche ’s Tecentriq helped people with early lung cancer live longer without their disease returning
Basel, 22 March 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III IMpower010 study evaluating Tecentriq® (atezolizumab), compared with best supportive care (BSC), met its primary endpoint of disease-free survival (DFS) at the interim analysis. Tecentriq showed a statistically significant im provement in DFS as adjuvant therapy following surgery and chemotherapy in all randomised Stage II-IIIA populations with non-small cell lung cancer (NSCLC). The magnitude of DFS benefit was particularly pronounced in the PD-L1-positive population. Follow-up will continue with planned analyses of DFS ...
Source: Roche Investor Update - March 22, 2021 Category: Pharmaceuticals Source Type: news

Pivotal Phase III study shows Roche ’s Tecentriq helped people with early lung cancer live longer without their disease returning
Basel, 22 March 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III IMpower010 study evaluating Tecentriq® (atezolizumab), compared with best supportive care (BSC), met its primary endpoint of disease-free survival (DFS) at the interim analysis. Tecentriq showed a statistically significant im provement in DFS as adjuvant therapy following surgery and chemotherapy in all randomised Stage II-IIIA populations with non-small cell lung cancer (NSCLC). The magnitude of DFS benefit was particularly pronounced in the PD-L1-positive population. Follow-up will continue with planned analyses of DFS ...
Source: Roche Media News - March 22, 2021 Category: Pharmaceuticals Source Type: news

Janssen Announces U.S. FDA Approval of PONVORY ™ (ponesimod), an Oral Treatment for Adults with Relapsing Multiple Sclerosis Proven Superior to Aubagio® (teriflunomide) in Reducing Annual Relapses and Brain Lesions
TITUSVILLE, N.J. – (March 19, 2021) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) approved PONVORY™ (ponesimod), a once-daily oral selective sphingosine-1-phosphate receptor 1 (S1P1) modulator, to treat adults with relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease.1,2,3 PONVORY™ offers MS patients superior efficacy in reducing annualized relapse rates compared to an established oral therapy and a proven safety profi...
Source: Johnson and Johnson - March 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Boston Scientific Receives FDA Approval for TheraSphere(TM) Y-90 Glass Microspheres
Treatment is the only radioembolization treatment approved for U.S. patients with hepatocellular carcinoma MARLBOROUGH, Mass., March 18, 2021 -- (Healthcare Sales & Marketing Network) -- Boston Scientific Corporation (NYSE: BSX) announced it has receiv... Devices, Oncology, FDA Boston Scientific, TheraSphere, Y-90, Glass Microspheres, radioembolization (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 18, 2021 Category: Pharmaceuticals Source Type: news

Integration analysis of m6A regulators and m6A-related genes in hepatocellular carcinoma
(Compuscript Ltd) Announcing a new article publication forBIO Integration journal. In this article the authors Jingdun Xie, Zhenhua Qi, Xiaolin Luo, Fang Yan, Wei Xing, Weian Zeng, Dongtai Chen and Qiang Li; from Sun Yat-sen University, Guangzhou, Guangdong, China discuss integration analysis of m6A regulators and m6A-related genes in hepatocellular carcinoma (HCC). (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 9, 2021 Category: International Medicine & Public Health Source Type: news

Roche provides update on Tecentriq US indication in prior-platinum treated metastatic bladder cancer
This study did not meet its primary endpoint of overall survival in the PD-L1 high patient population. Subsequently, the FDA designated the IMvigor130 study as the PMR which will still continue until the final analysis. However, as the treatment landscape in prior-platinum (second-line) mUC has rapidly evolved with the emergence of new treatment options, Roche is voluntarily withdrawing this indication in recognition of the principles of the Accelerated Approval Program.About Tecentriq Tecentriq is a monoclonal antibody designed to bind with a protein called Programmed Death Ligand-1 (PD-L1), which is expressed on tumour c...
Source: Roche Media News - March 8, 2021 Category: Pharmaceuticals Source Type: news